ArticleNPJ systems biology and applications2026
Untargeted metabolomics reveals organism specific biomarkers of carbapenem resistance in Klebsiella pneumoniae and Escherichia coli.
Article in NPJ systems biology and applications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Antimicrobial resistance (AMR) is one of the greatest global concerns due to the increase in the rate of AMR infections and the lack of development of antimicrobial agents to combat AMR. The development of resistance to carbapenems among common pathogenic bacteria, including Klebsiella pneumoniae and Escherichia coli, is particularly concerning because carbapenems are relied upon for the treatment of Gram-negative infections. Metabolomics offers an approach to identify biomarkers associated with metabolic mechanisms of carbapenem resistance. We analyzed 512 annotated metabolites from a total of 297 bacterial isolates spanning eight organisms. We discovered that the metabolome has greater variation between organisms compared with the resistance phenotype. As a result, we conducted organism-specific statistical analyses to discriminate carbapenem-resistant from carbapenem-sensitive isolates, and supervised learning models resulted in test set mean and standard deviation of area under the receiver operating characteristic curve of 0.822 ± 0.092 and 0.670 ± 0.110, and area under the precision-recall curve of 0.973 ± 0.016 and 0.653 ± 0.121, for Klebsiella pneumoniae and Escherichia coli, respectively. Feature selection using lasso logistic regression identified four metabolite biomarkers of carbapenem resistance in Klebsiella pneumoniae as 6-hydroxyphenazine-1-carboxamide (6-OH-Phz-1-Cam), N-Lactoyl tyrosine (N-Lac tyrosine), flavin adenine dinucleotide (FAD), and amalorin, and seven metabolite biomarkers in Escherichia coli as ibha#30, Cyclo(Leu-Lys), Asukamycin A-II, LPA 16:0, sphinganine, phytosphingosine, and PA 14:0/4:1;O. These unique metabolic signatures provide a vital foundation for exploring the emergence of AMR, warranting follow-up studies to clarify their role in carbapenem resistance and inform improved diagnostics and treatments for AMR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.